According to a recent study conducted over higher dose intake of opioid, it has been observed that such measures are not effective in reducing pain.
The researchers' team from Central Arkansas and Minneapolis VA health care systems and three universities suggest after studying available data that patients who got their opioid dosage increased were not helped by the higher dosage compared to those who continued with earlier dosage.
The Veterans Affairs study looked at prescribing data of more than 50,000 VA patients taking opioids. The findings led the study authors to warn, "Clinicians should exercise extreme caution when embarking on a path of increasing opioid doses to manage non-cancer pain."
The results were published in the January 9, issue of the journal 'Pain'.
A companion study by the same team that appeared online on January 15, in addition, confirmed the increased risk of side effects from higher doses.
Lead author Dr. Corey Hayes in a University of Arkansas for Medical Sciences report said, "You don't see the benefit, but you do see the risk. Our overall message is when you're thinking about increasing the dose, you need to realize the risk it brings, too."
Opioid medications relieve pain. They reduce the intensity of pain signals in the brain and affect areas of the brain controlling emotion, which diminishes the effects of pain stimuli. While opioids can help manage pain when taken correctly, they have a high risk of abuse and addiction.
Patients often receive increased doses of opioid medication because their pain may not be well-controlled on lower doses. People can also develop a tolerance to opioids over time, meaning a higher dose is needed to get the same effects. In these cases, prescribers must weigh the risks and rewards of escalating a patient's opioid dose.
Moreover, higher opioid doses can lead to a variety of side effects, such as constipation, dizziness, increased sensitivity to pain, and increased risk of substance use disorder.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
